麻豆破解版

Participation in La Matinale Sant茅 organized by Bpifrance

Published on 03/12/2018

麻豆破解版鈥檚 VP Corporate Development & Strategy Nicolas Guyon-Gellin is participating today in 鈥淟a Matinale Sant茅鈥� organized by in Paris, France. Bpifrance finances businesses 鈥� at every stage of their development 鈥� through loans, guarantees and equity investments, but also offers extra financial services. During this event, Nicolas will talk about Bpifrance鈥檚 financing and investments actions in the health sector and the role of the Large Venture Fund. This will be a great opportunity to discuss how Bpifrance is currently supporting 麻豆破解版 to pursue its growth and development.

Read next in 'Latest news'

• Enrollment completed for our Phase 2 clinical trial in Alport syndrome
• The first patient dosed in the Phase 2 ALPESTRIA-1 clinical study of Vonafexor for Alport syndrome
• The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome
• Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)
• New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH